Charles River, Antibody Discovery group, has integrated computational immunology, antibody engineering and phage display technologies into its comprehensive antibody discovery platforms that rapidly deliver antibody hits or optimised variants with a range of affinities, cross-species coverage, and improved drug-like characteristics. Charles River uses label-free biosensors and other bioanalytical assays to support biochemical/biophysical characterisation of biotherapeutic molecules including antibodies.
In this webinar, Christina Pettus, Senior Scientist, Charles River Laboratories, provides insights into how the company incorporates Octet® Bio-Layer Interferometry (BLI) into its monoclonal antibody discovery workflow for discovery campaigns, antibody optimisation, and IgG characterisation. The webinar elaborates on the use of the Octet® BLI for quality control of proteins, high throughput hit screening with crude single chain library clones, blocking/competition assays using crude and purified samples, and kinetic determination of antibody-antigen binding.
Key Learning Objectives from this webinar:
- • Use of the Octet® BLI platform for ultrahigh throughput hit screening and for off-rate ranking of crude periplasmic extract samples during early antibody discovery.
- • Octet® BLI applications in reagent quality control including binding interaction studies and rapid antibody quantitation using minimal and crude samples.
- • Setting up high throughput epitope blocking assays: premix and classical sandwich competition assays with crude periplasmic extracts or purified monoclonal antibodies.
- How to obtain kinetics measurements of purified monoclonal antibodies in a high throughput manner.